세계의 항정신병약 시장 : 클래스별, 적응증별 - 예측(2025-2030년)

The Antipsychotic Drugs Market was valued at USD 9.65 billion in 2023, expected to reach USD 10.42 billion in 2024, and is projected to grow at a CAGR of 8.01%, to USD 16.56 billion by 2030.

The antipsychotic drugs market encompasses medications primarily used to manage psychosis-related conditions such as schizophrenia and bipolar disorder. This market's scope extends to diverse mental health applications, including the treatment of severe depression and anxiety disorders. The necessity for these drugs is underscored by the rising incidence of mental health disorders and the expansion of awareness and diagnosis rates worldwide. The primary end-use sectors include hospitals, clinics, and rehabilitation centers, which utilize these medications to stabilize patients' psychological states and enhance their quality of life. Key growth factors for this market include the increasing prevalence of mental health conditions, advancements in drug formulations, and supportive mental health policies. Opportunities abound in developing next-generation antipsychotic drugs with fewer side effects and enhanced efficacy profiles. Investments in research focused on the genetic and biological underpinnings of psychiatric disorders could lead to personalized medication strategies, presenting a lucrative opportunity for businesses to innovate. Digital therapeutics, combined with pharmacological treatments, also represent a potential area for growth, especially as technology integrates into healthcare delivery. However, limitations affecting market growth include the high cost of drug development, stringent regulatory requirements, and the stigma associated with mental health disorders, which may hinder market expansion. Challenges such as side effects associated with existing antipsychotic drugs, including weight gain and metabolic issues, can deter patients from adherence to prescribed treatment regimes. To overcome these limitations, pharmaceutical companies might focus on reducing adverse effects through novel drug delivery systems, such as sustained-release formulations or transdermal patches. Overall, innovation in personalized medicine, leveraging artificial intelligence for drug discovery, and integrating comprehensive mental health services could drive significant business growth and transform the treatment landscape, highlighting the ongoing complex yet promising nature of the antipsychotic drugs market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antipsychotic Drugs Market

The Antipsychotic Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of psychosis and associated diseases
  • Rising drug approval from governments
  • Growing awareness regarding mental health and wellness
• Market Restraints
  • Patent expiry of established brands
• Market Opportunities
  • R&D and clinical trials for new antipsychotic drugs
  • Improvements in antipsychotic drug testing
• Market Challenges
  • Stringent regulatory framework and compliance

Porter's Five Forces: A Strategic Tool for Navigating the Antipsychotic Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antipsychotic Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antipsychotic Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antipsychotic Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antipsychotic Drugs Market

A detailed market share analysis in the Antipsychotic Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antipsychotic Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antipsychotic Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antipsychotic Drugs Market

A strategic analysis of the Antipsychotic Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antipsychotic Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alkermes, Inc., AMBOSS GmbH, Amgen Inc, Arlak Biotech, AstraZeneca PLC, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Dr. Reddy's Laboratories, Ltd., Eli Lilly and Company, Flagship Biotech International Pvt. Ltd., GlaxoSmithKline PLC, H. Lundbeck A/S, Johnson & Johnson Services Inc., Lifecare Neuro Products Ltd., Luye Pharma Group, Merck & Co., Inc., Novartis AG, Otsuka Pharmaceutical Co. Ltd., Pfizer, Inc., S. Karger AG, Seqirus Pty Ltd, Sumitomo Dainippon Pharma Co., Ltd., Teva Pharmaceutical Industries, Ltd., and Vanda Pharmaceuticals Inc..

Market Segmentation & Coverage

This research report categorizes the Antipsychotic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Class, market is studied across First Generation, Second Generation, and Third Generation. The First Generation is further studied across Haldo and Navane. The Second Generation is further studied across Geodon, Invega, Latuda, Risperdal, Seroquel, and Zyprexa. The Third Generation is further studied across Abilify.
• Based on Indication, market is studied across Bipolar Disorders, Dementia, Schizophrenia, and Unipolar Depression.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of psychosis and associated diseases
    • 5.1.1.2. Rising drug approval from governments
    • 5.1.1.3. Growing awareness regarding mental health and wellness
  • 5.1.2. Restraints
    • 5.1.2.1. Patent expiry of established brands
  • 5.1.3. Opportunities
    • 5.1.3.1. R&D and clinical trials for new antipsychotic drugs
    • 5.1.3.2. Improvements in antipsychotic drug testing
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory framework and compliance
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Antipsychotic Drugs Market, by Class

• 6.1. Introduction
• 6.2. First Generation
  • 6.2.1. Haldo
  • 6.2.2. Navane
• 6.3. Second Generation
  • 6.3.1. Geodon
  • 6.3.2. Invega
  • 6.3.3. Latuda
  • 6.3.4. Risperdal
  • 6.3.5. Seroquel
  • 6.3.6. Zyprexa
• 6.4. Third Generation
  • 6.4.1. Abilify

7. Antipsychotic Drugs Market, by Indication

• 7.1. Introduction
• 7.2. Bipolar Disorders
• 7.3. Dementia
• 7.4. Schizophrenia
• 7.5. Unipolar Depression

8. Americas Antipsychotic Drugs Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Antipsychotic Drugs Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Antipsychotic Drugs Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Alkermes, Inc.
• 3. AMBOSS GmbH
• 4. Amgen Inc
• 5. Arlak Biotech
• 6. AstraZeneca PLC
• 7. Bristol-Myers Squibb Company
• 8. Daiichi Sankyo Company, Limited
• 9. Dr. Reddy's Laboratories, Ltd.
• 10. Eli Lilly and Company
• 11. Flagship Biotech International Pvt. Ltd.
• 12. GlaxoSmithKline PLC
• 13. H. Lundbeck A/S
• 14. Johnson & Johnson Services Inc.
• 15. Lifecare Neuro Products Ltd.
• 16. Luye Pharma Group
• 17. Merck & Co., Inc.
• 18. Novartis AG
• 19. Otsuka Pharmaceutical Co. Ltd.
• 20. Pfizer, Inc.
• 21. S. Karger AG
• 22. Seqirus Pty Ltd
• 23. Sumitomo Dainippon Pharma Co., Ltd.
• 24. Teva Pharmaceutical Industries, Ltd.
• 25. Vanda Pharmaceuticals Inc.